Blue chip – Jamiron http://jamiron.net/ Mon, 29 Nov 2021 16:53:52 +0000 en-US hourly 1 https://wordpress.org/?v=5.8.1 https://jamiron.net/wp-content/uploads/2021/10/icon-20-120x120.png Blue chip – Jamiron http://jamiron.net/ 32 32 3 Best-in-Class Resilient Stocks to Buy Now https://jamiron.net/3-best-in-class-resilient-stocks-to-buy-now/ Sat, 27 Nov 2021 11:04:29 +0000 https://jamiron.net/3-best-in-class-resilient-stocks-to-buy-now/ Blue-chip, resilient stocks are attractive in today’s market environment What are some of the typical qualities that make a business resilient? It is generally a business that can generate profits in almost any economic environment. With a strong brand and products or services that are always in constant demand, investors can count on these types […]]]>

Blue-chip, resilient stocks are attractive in today’s market environment

What are some of the typical qualities that make a business resilient? It is generally a business that can generate profits in almost any economic environment. With a strong brand and products or services that are always in constant demand, investors can count on these types of businesses through thick and thin. Blue-chip stocks are a good example of this, as they are companies with strong balance sheets, stable cash flows, and business models that can stand the test of time.

Adding resilient blue-chip stocks to your portfolio makes a lot of sense right now given recent market volatility. With so many confusing factors at play in the market and in the economy, targeting companies that offer reliability could be one of the smartest things to do right now.

Let’s take a look at 3 resilient blue chip stocks to buy now.

If you’re interested in a top tech company that has consistently proven itself capable of adapting to new trends over the years, Microsoft certainly fits the bill. The software company has pivoted to cloud computing at the perfect time, and Microsoft Azure now offers whole new growth opportunities for long-term shareholders. Products like Windows, Microsoft Office, Office 365, Sharepoint, and more are some of the world’s most popular business software options, which means the business is consistently getting the cash flow it can. reinvest in high growth areas such as Azur.

Microsoft’s revenue grew 22% year-over-year in the second quarter to $ 45.3 billion, and the company continues to reward its shareholders with consistent profit growth. There’s also a lot to like about the company’s XBOX Series X gaming console, which could deliver a nice increase in profits for Microsoft as supply chain issues start to diminish. The bottom line here is that Microsoft has a rock solid net cash position, strong upward growth, and a history of building innovative new products, making it one of the best blue chip stocks around. .

Even with Pfizer trading around all-time highs, this blue chip company could end up being a good deal at current levels. It is a global research-based biopharmaceutical company that offers investors the right balance between a strong existing drug portfolio and an intriguing pipeline of new drugs that could become future cash cows. With top-selling drugs like Prevnar, Ibrance and Eliquis, investors here can count on stable earnings quarter after quarter. Global prescription drug sales are expected to grow at a compound annual growth rate of 7.4% from 2020 to 2026, indicating to us that there is a lot of money to be made for a company like Pfizer.

Investors are likely already aware of the company’s COVID-19 vaccine, which saw Pfizer increase revenue 134% year-on-year to $ 24.1 billion in the third quarter. The company’s COVID antiviral treatment pills could be another strong growth driver, and FDA approval of the treatment could cause stocks to skyrocket in the coming weeks. Finally, the company’s 3.05% dividend yield is very attractive, and Pfizer also has a history of stock buyback programs that make it a great choice for long-term investors.

Companies involved in the healthcare industry can certainly offer reliability, especially in the aftermath of the global pandemic. McKesson is a solid choice as the largest pharmaceutical distributor in North America, which means the company plays a vital role in keeping our country healthy. In addition to pharmaceuticals, McKesson provides health information technology, medical supplies and care management tools, which means it serves a wide range of healthcare clients. What is perhaps most appealing here is the fact that McKesson has a truly dominant position in the market, as it is one of three companies that operate as a pharma wholesale and distribution oligarchy. .

The company reported total second-quarter revenue of $ 66.6 billion, up 9% year-on-year, and raised its outlook for fiscal 22, which is another good reason to consider adding actions. McKesson also plays an important role in the fight against COVID-19 and has seen strong demand for products such as COVID-19 tests, vaccines and more in recent quarters. Finally, the fact that McKesson is selling part of its European business is another advantage to consider, as this will allow the company to focus on the areas with the highest growth in the business in the future.

Should you invest $ 1,000 in McKesson now?

Before you consider McKesson, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts are quietly asking their clients to buy now before the broader market takes hold … and McKesson was not on the list.

While McKesson currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.

See the 5 actions here

Companies mentioned in this article

Compare these actions Add these actions to my watchlist


Source link

]]>
Blue-Chip Drugmaker Stops On Latest Covid Treatment Data https://jamiron.net/blue-chip-drugmaker-stops-on-latest-covid-treatment-data/ Fri, 26 Nov 2021 15:13:57 +0000 https://jamiron.net/blue-chip-drugmaker-stops-on-latest-covid-treatment-data/ Merck & Co reported updated data from an advanced study of its investigational drug Covid-19 Although most Covid-19 treatment stocks are increasing this morning, following news of a new Covid-19 variant, pharmaceutical giant Merck & Co., Inc. (NYSE: MRK) is down 4.3% to trade at $ 78.76 at last check. The First Order name reported […]]]>

Merck & Co reported updated data from an advanced study of its investigational drug Covid-19

Although most Covid-19 treatment stocks are increasing this morning, following news of a new Covid-19 variant, pharmaceutical giant Merck & Co., Inc. (NYSE: MRK) is down 4.3% to trade at $ 78.76 at last check. The First Order name reported updated data from an advanced stage study of its investigational pill Covid-19, which showed a lower rate of effectiveness in reducing the risk of hospitalization and death than observed in a previous study, with a reduction of 30% compared to its previous 50%.

After a bearish spread after its recent all-time high of $ 91.40 on November 4, MRK is struggling to break above the $ 84 zone. Returning to its lowest level since mid-October, the 150-day moving average persists just below as potential support. It should be noted, however, that the stock could rebound in the short term after all this negative price action, based on its Relative Strength Index (RSI) of 27, which is in “oversold” territory.

Analysts are divided on MRK, with seven of 13 covers rated “strong buy” and six rated “lukewarm”. Meanwhile, the 12-month consensus price target of $ 96.17 is a 21.6% premium from last night’s close.

In the options booths, calls have been more popular than usual over the past 10 weeks. The 50-day buy / sell volume ratio of Merck stock of 5.59 on the International Securities Exchange (ISE), Cboe Options Exchange (CBOE) and NASDAQ OMX PHLX (PHLX) is greater than 84% of readings from last year.

Today, although calls are still winning in absolute terms, the volume of wagers is double what is generally seen at this stage. The December 100 and 80 calls are the most active so far today, followed by the weekly put 11/26 78 strikes, which expires at the end of the day, and where new positions are bought to open.


Source link

]]>
Why you should consider this top dividend paying stock for your portfolio https://jamiron.net/why-you-should-consider-this-top-dividend-paying-stock-for-your-portfolio/ Thu, 25 Nov 2021 14:45:00 +0000 https://jamiron.net/why-you-should-consider-this-top-dividend-paying-stock-for-your-portfolio/ AAs dividend investors can attest, choosing the right stocks for your diversified portfolio is important to ensure long-term success. What characteristics do strong dividend stocks typically have? The best are consistently increasing their earnings and earnings per share (EPS), have strong balance sheets, and maintain low payout ratios. I believe the asset manager T. Rowe […]]]>

AAs dividend investors can attest, choosing the right stocks for your diversified portfolio is important to ensure long-term success. What characteristics do strong dividend stocks typically have? The best are consistently increasing their earnings and earnings per share (EPS), have strong balance sheets, and maintain low payout ratios.

I believe the asset manager T. Rowe Price Group (NASDAQ: TROW) tick all of these boxes. But is the stock a buy right now? Let’s dig in and see if we can find an answer.

Image source: Getty Images.

T. Rowe Price Group Reports Impressive Third Quarter

The company narrowly missed third quarter analyst revenues and non-GAAP (adjusted) EPS estimates. And while it may seem daunting, it’s important to put these results in the right context.

T. Rowe Price has met or exceeded analysts’ expectations for revenue and Adjusted EPS in the 10 consecutive quarters leading up to the third quarter. This suggests that the company has fallen victim to its own success. It is likely that analysts have slightly overestimated what its financial results would be for the third quarter.

T. Rowe Price reported third quarter net sales of $ 1.95 billion, up 22.5% from a year ago. So, despite a 1% drop in revenues of $ 1.97 billion forecast by analysts, the company continues to grow very rapidly. How did he manage to do this?

Thanks to the continued appreciation in the stock markets over the past year, the company’s average assets under management grew 27.5% year-over-year to $ 1.65 trillion in the third trimester. It continued to generate the vast majority of its income from investment advisory fees (92.8% of third quarter net income) assessed on the basis of assets under management, which explains the increase in net income over the period. trimester.

And while revenue was much higher in the third quarter, its adjusted operating expenses only increased 15.3% year-over-year to $ 957 million in the quarter. This is what led T. Rowe Price’s adjusted net margin to rise 150 basis points to 39.3% in the quarter. The company’s combination of a higher revenue base and higher net margins resulted in an increase in adjusted EPS of 28.2% year-over-year to $ 3.27 in the third quarter.

Since S&P 500 Established its 66th all-time high of 2021 last week, T. Rowe Price is a prime candidate to benefit from such a strong stock market. Against this record backdrop, it makes sense that analysts expect the company to post 16% annual profit growth over the next five years.

Debt free with lots of cash

A testament to the discipline of T. Rowe Price’s management team, the company has a fortress-like track record. The absence of long-term debt is of particular interest as Federal Reserve Chairman of St. Louis, James Bullard, is planning two rate hikes next year. Since the company has no debt, it does not have to worry about the magnitude of the interest rate hike.

With a balance of $ 5.34 billion in cash and discretionary investments at the end of the third quarter, the company has enough cash to be able to redeem 11.5% if it chooses to do so. This is based on T. Rowe Price’s market cap of $ 46.4 billion at the current share price of $ 207.

Simply put, it has a lot more flexibility than most companies to reward its shareholders with dividend increases, share buybacks, and special dividends.

A growth share with an updated dividend

While T. Rowe Price is a fundamentally healthy company, it seems the market isn’t fully appreciating the stock.

It trades at a forward price-to-earnings ratio of 15.4, which is well below the asset management industry average of 17.7. T. Rowe Price not only has a clear advantage over most asset managers with a debt-free balance sheet, but his growth prospects are also very promising. The company’s potential for annual profit growth of 16% over the next five years ranks it in the top 10% of 202 asset managers.

And while investors wait for the company to rightfully score a higher valuation, they may receive a well-hedged 2.1% dividend yield that is better than the market. Overall, this is why I still think T. Rowe Price Group is a top notch stock worth buying.

10 stocks we prefer over T. Rowe Price Group
When our award-winning team of analysts have stock advice, it can pay off to listen. After all, the newsletter they’ve been running for over a decade, Motley Fool Equity Advisor, has tripled the market. *

They just revealed what they think are the ten best stocks investors can buy right now … and T. Rowe Price Group was not one of them! That’s right – they think these 10 stocks are even better buys.

See the 10 actions

* The portfolio advisor returns on November 10, 2021

Kody Kester owns shares of T. Rowe Price Group. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


Source link

]]>
Is the T. Rowe Price Blue Chip Growth Fund (TRBCX) a great choice for mutual funds right now? https://jamiron.net/is-the-t-rowe-price-blue-chip-growth-fund-trbcx-a-great-choice-for-mutual-funds-right-now/ Mon, 22 Nov 2021 12:00:04 +0000 https://jamiron.net/is-the-t-rowe-price-blue-chip-growth-fund-trbcx-a-great-choice-for-mutual-funds-right-now/ IIf you’re looking for the fund category of the mutual fund stocks report, T. Rowe Price Blue Chip Growth Fund (TRBCX) might be a potential place to start. TRBCX holds a Zacks Mutual Fund Rank of 3 (Hold), which is based on nine forecasting factors such as size, cost and past performance. Fund History / […]]]>

IIf you’re looking for the fund category of the mutual fund stocks report, T. Rowe Price Blue Chip Growth Fund (TRBCX) might be a potential place to start. TRBCX holds a Zacks Mutual Fund Rank of 3 (Hold), which is based on nine forecasting factors such as size, cost and past performance.

Fund History / Manager

TRBCX is part of the T. Rowe Price family, based in Baltimore, MD. Since the T. Rowe Price Blue Chip Growth Fund debuted in June 1993, TRBCX has garnered over $ 59.90 billion in assets. Larry J. Puglia is the current fund manager and has held this position since June 1993.

Performance

Obviously, what investors are looking for in these funds is a strong performance relative to their peers. TRBCX has a 5-year total annualized return of 24.06% and is in the top third of its class. Investors who prefer to analyze shorter time frames should look at its 3-year annualized total return of 25.52%, which puts it in the middle third over that time frame.

When looking at the performance of a fund, it is also important to note the standard deviation of returns. The lower the standard deviation, the less volatility the fund experiences. Over the past three years, the standard deviation of TRBCX has stood at 19.04%, compared to an average of 16.45% for the category. The fund’s standard deviation over the past 5 years is 16.59% compared to the category average of 13.56%. This makes the fund more volatile than its peers over the past five years.

Risk factors

Investors should note that the fund has a beta of 0.99 over 5 years, which means it is hypothetically as volatile as the market as a whole. Since alpha represents the performance of a portfolio on a risk-adjusted basis relative to a benchmark, which is the S&P 500 in this case, it is worth paying attention to this metric as well. With a positive alpha of 4.7, the managers of this portfolio are adept at selecting stocks that generate returns above the benchmark.

Holdings

Examining the stock holdings of a mutual fund is also a valuable exercise. This can show us how the manager applies his stated methodology, as well as whether there are inherent biases in his approach. For this particular fund, the focus is primarily on stocks traded in the United States.

As of the last filing date, the mutual fund had 92.94% of its assets in stocks, which have an average market capitalization of $ 603.33 billion. The fund has the most exposure to the following market sectors:

  1. Technology
  2. Retail business
  3. Finance

Expenses

The costs are increasingly important for investing in mutual funds, and particularly as competition intensifies in this market. And all else being equal, a lower-cost product will outperform its otherwise identical counterpart, so it’s critical for investors to take a closer look at these metrics. In terms of fees, TRBCX is a no-load fund. It has an expense ratio of 0.69% compared to the category average of 1.02%. From a cost perspective, TRBCX is actually cheaper than its peers.

This fund requires a minimum initial investment of $ 2,500, and each subsequent investment should be at least $ 100.

Final result

Overall, T. Rowe Price Blue Chip Growth Fund (TRBCX) has a neutral Zacks Mutual Fund ranking, and in conjunction with its comparatively strong performance, medium downside risk and lower fees, this fund seems like a choice. somewhat average for investors right now.

For more information on this product, or to compare it to other mutual funds in the Mutual Fund Report, be sure to go to www.zacks.com/funds/mutual-funds for more information. If you’d like to check out our inventory reports as well, be sure to go to Zacks.com to see all of the great tools we have to offer, including our proven Zacks Rankings.

5 actions in the process of doubling

Each has been handpicked by a Zacks expert as the # 1 favorite stock to earn + 100% or more in 2021. Previous recommendations have climbed + 143.0%, + 175.9%, +498 , 3% and + 673.0%.

Most of the stock in this report is flying under Wall Street’s radar, which provides a great opportunity to get into the ground floor.

Today, discover these 5 potential circuits >>

Click to get this free report

Get Your Free (TRBCX): Fund Analysis Report

To read this article on Zacks.com, click here.

Zacks investment research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


Source link

]]>
Should you buy this Blue Chip Biotech share? https://jamiron.net/should-you-buy-this-blue-chip-biotech-share/ Sun, 21 Nov 2021 13:00:00 +0000 https://jamiron.net/should-you-buy-this-blue-chip-biotech-share/ TThis is arguably the most difficult time for an income investor in decades. On the one hand, the S&P 500 returns less than 1.3%, which is very close to its all-time low of 1.1% in 2000. At the same time, the annual inflation rate of 6.2% last month hit a 31-year high. Anyone sitting on […]]]>

TThis is arguably the most difficult time for an income investor in decades. On the one hand, the S&P 500 returns less than 1.3%, which is very close to its all-time low of 1.1% in 2000. At the same time, the annual inflation rate of 6.2% last month hit a 31-year high. Anyone sitting on cash and waiting for a market correction is like watching your money soar as your capital loses purchasing power. So what should an income investor do?

Fortunately, there are still some viable, high yielding options that income investors can consider. Let’s take a look at three reasons why pharmaceutical stocks AbbVie (NYSE: ABBV) could be one of those options.

Image source: Getty Images.

AbbVie consistently exceeds expectations

When AbbVie released its third quarter results on October 29, the company managed to beat analysts’ estimates for non-GAAP revenue and earnings per share (EPS) for the 11th consecutive quarter. The company posted third-quarter revenue of $ 14.34 billion, equivalent to a growth rate of 11.3% compared to the same period last year. That’s what led AbbVie to beat analysts’ forecast of $ 14.3 billion in third-quarter revenue by 0.3%.

AbbVie’s largest segment, the immunology segment led by Humira, followed by Skyrizi and Rinvoq, contributed 60.5% of total revenue growth in the third quarter. Humira’s revenue edged up 5.6% year-over-year to $ 5.43 billion in the third quarter, contributing nearly a third (32.2%) of revenue growth in AbbVie’s immunology segment in the third quarter.

Without a doubt, the most encouraging result of AbbVie’s third quarter is that its next-generation immunology drugs Skyrizi and Rinvoq saw their combined revenue increase 92.2% to $ 1.25 billion. This represented the remaining 67.8% of the growth in the immunology segment. And before Humira’s U.S. patent expired in 2023, Skyrizi and Rinvoq’s overall share of immunology segment revenue increased from 11.2% to 18.7% in the third quarter.

Overall, AbbVie appears well positioned to rebound strongly after Humira’s imminent loss of exclusivity in the United States via Skyrizi, Rinvoq and other drugs such as the antipsychotic Vraylar, which increased its revenue. third-quarter 29% year-over-year to $ 461 million. That’s why analysts predict that AbbVie will show annual adjusted EPS growth of 4.5% over the next five years despite the fall in Humira’s patents. AbbVie reported third quarter adjusted EPS of $ 3.33, representing a growth rate of 17.7% from the previous year. It also beat analyst consensus of $ 3.22 in adjusted third-quarter EPS by 3.4%.

AbbVie’s strong performance in the third quarter and year-to-date prompted the company to slightly raise its midpoint forecast for Adjusted EPS for this year, from $ 12.57 to $ 12.65. The updated mid-term forecast for this year would be a 19.8% year-over-year growth rate in adjusted EPS from the $ 10.56 reported last year. These encouraging prospects help to explain why the board of directors of the company announced a sharp increase of 8.5% of its quarterly dividend as of the dividend paid next February.

A fair and improving balance sheet

AbbVie is a growing company, which is important for dividend growth investors. But does the company have a sufficiently healthy balance sheet to pay its dividend during a temporary drop in profitability? Let’s turn to the interest coverage ratio to answer this question, which measures the ease with which a company can meet its interest expense obligations with its earnings before interest and taxes (EBIT).

Its interest coverage ratio fell from four in the first nine months of last year ($ 6.57 billion in EBIT / $ 1.66 billion in interest expense) to 5.8 over the course of the last year. the first nine months of this year ($ 10.53 billion EBIT / $ 1.81 billion interest expense). This demonstrates that the company continues to move in the right direction in integrating Allergan’s assets into its business after the acquisition closes in May 2020.

A blue chip at an attractive price

Even though AbbVie’s fundamentals seem solid, the stock is strongly discounted by the market. Primarily motivated by concerns over the cliff of Humira’s US patents which I think are exaggerated based on Skyrizi and Rinvoq’s huge growth trajectories.

In fact, AbbVie’s forward P / E ratio of 8.4 at its current price of $ 116 per share is much lower than the drugmaker’s average forward P / E ratio of 11.3. This gives income investors a chance to pick up AbbVie shares and its well-hedged 4.5% return before the market warms up and puts it to a higher valuation multiple.

10 actions we prefer over AbbVie
When our award-winning team of analysts have stock advice, it can pay off to listen. After all, the newsletter they’ve been running for over a decade, Motley Fool Equity Advisor, has tripled the market. *

They just revealed what they think are the ten best stocks investors can buy right now … and AbbVie was not one of them! That’s right – they think these 10 stocks are even better buys.

See the 10 actions

* The portfolio advisor returns on November 10, 2021

Kody Kester owns shares of AbbVie. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


Source link

]]>
Romgaz leads first-rate declines on Bucharest stock exchange, stock indices end week in the red https://jamiron.net/romgaz-leads-first-rate-declines-on-bucharest-stock-exchange-stock-indices-end-week-in-the-red/ Fri, 19 Nov 2021 17:43:00 +0000 https://jamiron.net/romgaz-leads-first-rate-declines-on-bucharest-stock-exchange-stock-indices-end-week-in-the-red/ BUCHAREST (Romania), November 19 (SeeNews) – Romanian private health service provider Romgaz [BSE:SNG], led the declines among the Bucharest Stock Exchange (BVB) blue chips on Friday, according to stock exchange data. Total turnover of BVB shares amounted to some 47.5 million lei ($ 10.9 million / 9.6 million euros) on Friday, compared to 51 million […]]]>

BUCHAREST (Romania), November 19 (SeeNews) – Romanian private health service provider Romgaz [BSE:SNG], led the declines among the Bucharest Stock Exchange (BVB) blue chips on Friday, according to stock exchange data.

Total turnover of BVB shares amounted to some 47.5 million lei ($ 10.9 million / 9.6 million euros) on Friday, compared to 51 million lei on Thursday, the report said. BVB website.

Romgaz dominated the blue chip declines on Friday, as its share price fell 2.79% to 34.8 lei.

Romanian real estate developer One United Properties [BSE:ONE] share price rose 1.24% to 2.6 lei in the largest trading turnover during the session, to 23.09 million lei. One United announced on Friday that it will indirectly acquire 54.43% of the local shopping center Bucur Obor SA [BSE:BUCU] for 65 million lei.

Blue chip lender Banca Transilvania [BSE:TLV] fell 0.38% to 2.59 lei to reach the second turnover of the day with 4.11 million lei.

The premier oil and gas group OMV Petrom [BSE:SNP] traded 2.24% down to 0.4795 lei in the third highest turnover of the day of 3.36 million lei.

Details follow:

BET 12,559.61 -1.51%
BET-TR 22,227.10

-1.50%

BET-FI 51,705.29 -0.84%
PARI-NG 849.17 -2.10%
PARI-XT 1,109.15 -1.44%
PARI-XT-TR 1,962.20 -1.43%
PARI-BK 2475.31 -1.42%
ROTX 26,830.36 -1.73%
BETAeRO 1,009.00 -0.44%

-1.50%

BET is the first index developed by BVB and represents the benchmark index for the local capital market. The BET reflects the performance of the most traded companies on the BVB regulated market, excluding financial investment companies (SIF). It now includes 20 companies.

BET-TR is the first total return index launched by BVB. It is based on the structure of the benchmark BET market index. BET-TR tracks changes in the price of its component shares and is adjusted to also reflect dividends paid by the constituent companies.

The BET-FI is the first sector index launched by the BVB and reflects the price variations of RIS and other similar entities.

BET-BK was designed to be used as a benchmark by asset managers and other institutional investors.

BET-NG is a sector index that reflects the evolution of all companies listed on BVB’s regulated market included in the energy and related utilities sector. The maximum index weight that a company can hold is 30%.

BET-XT tracks the price movements of the 25 most listed companies on the BVB regulated market, including RIS.

BET-XT-TR is the total return version of the BET-XT index, which includes the 25 most traded Romanian companies listed on the BVB.

ROTX is an index developed by BVB in collaboration with the Vienna Stock Exchange. It follows, in real time, the price changes of blue chip shares traded on the Bucharest Stock Exchange.

BET AeRO is the first index for the AeRO market developed by BVB that reflects the price performance of representative companies listed on the AeRO market that meet the criteria of liquidity and free float market capitalization. It is a free float market capitalization weighted index, with a maximum weighting of 15% for any component of the index.

(1 euro = 4.9490 lei)

Banca Transilvania SA is one of the largest banks in South East Europe. For more references, take a look at the Top 100 Banks


Source link

]]>
Sofia stock indexes close lower, Eurohold tops blue chip declines https://jamiron.net/sofia-stock-indexes-close-lower-eurohold-tops-blue-chip-declines/ Wed, 17 Nov 2021 15:05:00 +0000 https://jamiron.net/sofia-stock-indexes-close-lower-eurohold-tops-blue-chip-declines/ SOFIA (Bulgaria), Nov. 17 (SeeNews) – All Bulgarian Stock Exchange (ESB) indices fell on Wednesday, with the SOFIX index losing 0.43% to 608.61 points. SOFIX was mainly pulled down by a 2.78% drop in shares of financial and energy group Eurohold Bulgaria [BUL:EUGBG]. In total, 5,140 Eurohold shares traded at an average price of 2.1299 […]]]>

SOFIA (Bulgaria), Nov. 17 (SeeNews) – All Bulgarian Stock Exchange (ESB) indices fell on Wednesday, with the SOFIX index losing 0.43% to 608.61 points.

SOFIX was mainly pulled down by a 2.78% drop in shares of financial and energy group Eurohold Bulgaria [BUL:EUGBG]. In total, 5,140 Eurohold shares traded at an average price of 2.1299 lev. A day earlier, Eurohold gained 4.85%.

A 4.55% drop in fertilizer producer Neochim [BUL:NEOH] weighed on the BGBX40 index, which tracks the 40 most traded stocks on the Sofia Stock Exchange, and the BGTR30 index, in which companies with a free float of at least 10% have equal weight.

The BGBX40 fell 0.34% to 138.27 points, while the BGTR30 fell 0.13% to 665.11 points.

The BGREIT index, which tracks seven real estate investment trusts, closed down 0.25% at 166.11 points on Wednesday due to a 0.93% drop in the share price of Bulgarian real estate fund REIT [BUL:BREF].

Total turnover in the main BSE market rose to 1.5 million levs (866,300/766,900 euros) on Wednesday from 1.3 million levs on Tuesday.

The most traded company on Wednesday was real estate company Velgraf Asset Management [BUL:VAM]. No less than 95,500 shares of the company traded 0.47% less at an average price of 4.2,800 Lev, generating 408,700 Lev in turnover for the day.

(1 euro = 1.95583 lev)


Source link

]]>
Electrica tops first-rate lows on Bucharest stock exchange, indices drop https://jamiron.net/electrica-tops-first-rate-lows-on-bucharest-stock-exchange-indices-drop/ Mon, 15 Nov 2021 16:12:00 +0000 https://jamiron.net/electrica-tops-first-rate-lows-on-bucharest-stock-exchange-indices-drop/ BUCHAREST (Romania), November 15 (SeeNews) – Romanian electricity supplier and distributor Electrica [BSE:EL] led the declines among the Bucharest Stock Exchange (BVB) blue chips on Monday, according to stock exchange data. Total turnover of BVB shares fell to 43 million lei ($ 9.95 million / 8.69 million euros) on Monday, from 53 million lei on […]]]>

BUCHAREST (Romania), November 15 (SeeNews) – Romanian electricity supplier and distributor Electrica [BSE:EL] led the declines among the Bucharest Stock Exchange (BVB) blue chips on Monday, according to stock exchange data.

Total turnover of BVB shares fell to 43 million lei ($ 9.95 million / 8.69 million euros) on Monday, from 53 million lei on Friday, according to BVB data.

Blue chip lender Banca Transilvania [BSE:TLV] lost 0.57% to 2.6350 lei in the day’s highest turnover of 9.89 million lei.

Electrica dominated the blue chip declines on Monday, as its share price fell 4.63% to 10.7 lei in the second highest turnover of the day of 5.5 million lei.

Top-rated investment fund Fondul Proprietatea [BSE:FP] rose 1.45% to 1.8240 lei in the third highest turnover of the day of 4.5 million lei. The fund announced that it recorded a net profit of 3.097 billion lei in the nine months leading up to September, compared to a net loss of 726.4 million lei in the same period of 2020.

Details follow:

Index Closing value Daily change
BET 12 832.89 0.00%
BET-TR 22,709.92 -0.01%
BET-FI 52,038.20 0.36%
BETPlus 1,815.15 0.11%
PARI-NG 868.39 -0.42%
PARI-XT 2,000.84 -0.02%
PARI-XT-TR 1,879.43 -0.09%
PARI-BK 2,526.90 -0.18%
ROTX 27,395.75 -0.12%
BETAeRO 1,017.05 -0.60%

BET is the first index developed by BVB and represents the benchmark index for the local capital market. The BET reflects the performance of the most traded companies on the BVB regulated market, excluding financial investment companies (SIF). It now includes 20 companies.

BET-TR is the first total return index launched by BVB. It is based on the structure of the benchmark BET market index. BET-TR tracks changes in the price of its component shares and is adjusted to also reflect dividends paid by the constituent companies.

BET-FI is the first sector index launched by the BVB and reflects the price variations of RIS and other similar entities.

BET-BK has been designed to be used as a benchmark by asset managers and other institutional investors.

BET-NG is a sector index which reflects the evolution of all companies listed on BVB’s regulated market included in the energy and related utilities sector. The maximum index weight that a company can hold is 30%.

BET-XT tracks the price movements of the 25 most listed companies on the BVB regulated market, including RIS.

BET-XT-TR is the total return version of the BET-XT index, which includes the 25 most traded Romanian companies listed on the BVB.

ROTX is an index developed by BVB in collaboration with the Vienna Stock Exchange. It follows, in real time, the price changes of blue chip shares traded on the Bucharest Stock Exchange.

BET AeRO is the first index for the AeRO market developed by BVB that reflects the price performance of representative companies listed on the AeRO market that meet the criteria of liquidity and free float market capitalization. It is a free float market capitalization weighted index, with a maximum weight of 15% for any component of the index.

(1 euro = 4.9489 lei)

Banca Transilvania SA is one of the largest banks in South East Europe. For more references, take a look at the Top 100 Banks


Source link

]]>
Bucharest stock indices sink further, TeraPlast leads blue chip declines https://jamiron.net/bucharest-stock-indices-sink-further-teraplast-leads-blue-chip-declines/ Tue, 09 Nov 2021 16:06:00 +0000 https://jamiron.net/bucharest-stock-indices-sink-further-teraplast-leads-blue-chip-declines/ BUCHAREST (Romania), Nov. 9 (SeeNews) – Most of the Bucharest Stock Exchange (BVB) stock indexes continued to lose ground on Tuesday as PVC pipe and fittings manufacturer TeraPlast SA [BSE:TRP] drove blue chip declines, according to stock exchange data. Total turnover of BVB shares was some 33.5 million lei ($ 7.8 million / € 6.8 […]]]>

BUCHAREST (Romania), Nov. 9 (SeeNews) – Most of the Bucharest Stock Exchange (BVB) stock indexes continued to lose ground on Tuesday as PVC pipe and fittings manufacturer TeraPlast SA [BSE:TRP] drove blue chip declines, according to stock exchange data.

Total turnover of BVB shares was some 33.5 million lei ($ 7.8 million / € 6.8 million) on Tuesday, compared to Lei 90.95 million on Monday, it said. the BVB website.

Prime lender Banca Transilvania [BSE:TLV] share price fell 0.78% to 2.5550 lei in the largest trading turnover during the session, from 6.7 million lei.

TeraPlast led the blue chip declines, with its share price falling 3.59% to 1.0740 lei lei in the second highest daily turnover of 4.73 million lei.

Blue-chip Nuclearelectrica [BSE:SNN], the operator of Romania’s only Cernavoda nuclear power plant, lost 1.23% to 44.1 lei in the third day’s turnover of 4.38 million lei.

Details follow:

BET 12,847.75 -0.10%
BET-TR 22,732.31 -0.10%
BET-FI 51 555.62 -0.52%
PARI-NG 892.30 -0.17%
PARI-XT 1134.36 -0.12%
PARI-XT-TR 2,006.49 -0.13%
PARI-BK 2,546.74 -0.02%
ROTX 27,494.37 0.00%
BETAeRO 1,023.32 -0.68%

BET is the first index developed by BVB and represents the benchmark index for the local capital market. The BET reflects the performance of the most traded companies on the BVB regulated market, excluding financial investment companies (SIF). It now includes 20 companies.

BET-TR is the first total return index launched by BVB. It is based on the structure of the benchmark BET market index. BET-TR tracks changes in the price of its component stocks and is adjusted to also reflect dividends paid by the constituent companies.

BET-FI is the first sector index launched by the BVB and reflects the price variations of RIS and other similar entities.

BET-BK was designed to be used as a benchmark by asset managers and other institutional investors.

BET-NG is a sector index which reflects the evolution of all companies listed on BVB’s regulated market included in the energy and related utilities sector. The maximum index weight that a company can hold is 30%.

BET-XT tracks the price changes of the 25 most listed companies on the BVB regulated market, including RIS.

BET-XT-TR is the total return version of the BET-XT index, which includes the 25 most traded Romanian companies listed on the BVB.

ROTX is an index developed by BVB in collaboration with the Vienna Stock Exchange. It follows, in real time, the price changes of blue chip shares traded on the Bucharest Stock Exchange.

BET AeRO is the first index for the AeRO market developed by BVB that reflects the price performance of representative companies listed on the AeRO market that meet the criteria of liquidity and free float market capitalization. It is a free float market capitalization weighted index, with a maximum weighting of 15% for any component of the index.

(1 euro = 4.9482 lei)

Banca Transilvania SA is one of the largest banks in South East Europe. For more references, take a look at the Top 100 Banks


Source link

]]>
Enbridge earnings: another strong quarter for blue-chip equities https://jamiron.net/enbridge-earnings-another-strong-quarter-for-blue-chip-equities/ Fri, 05 Nov 2021 18:30:00 +0000 https://jamiron.net/enbridge-earnings-another-strong-quarter-for-blue-chip-equities/ Image source: Getty Images This morning before the market opens, Enbridge (TSX: ENB) (NYSE: ENB), the Canadian energy giant, announced its third quarter results for 2021. Energy is one of the hottest industries right now, as the world is recovering from the pandemic. And with several Canadian energy stocks already posting spectacular numbers this quarter, […]]]>

Image source: Getty Images

This morning before the market opens, Enbridge (TSX: ENB) (NYSE: ENB), the Canadian energy giant, announced its third quarter results for 2021. Energy is one of the hottest industries right now, as the world is recovering from the pandemic. And with several Canadian energy stocks already posting spectacular numbers this quarter, investors were eagerly awaiting Enbridge’s progress.

What happened to Enbridge’s third quarter report?

As expected, the overall figure is a 23% increase in Enbridge profits thanks to both higher prices and a recovery in volumes. Enbridge shares transported 2.6 million barrels per day (b / d) on its Mainline, up 4.6% from the same quarter last year.

Enbridge reported adjusted earnings of $ 1.2 billion, up from $ 961 million in the same quarter last year. On a per share basis, Enbridge increased its EPS from $ 0.48 last year to $ 0.59 this year.

In addition to net income, Enbridge also released other very impressive figures. Its adjusted EBITDA reached $ 3.3 billion in the quarter, up from $ 3 billion in the same period last year. Its distributable cash flow per share also increased to $ 1.13 from $ 1.03 a year ago.

In addition to these impressive numbers, Enbridge shares also briefed investors on some key developments this quarter.

With the replacement of Enbridge’s Line 3 now in service and the company’s acquisition of a major North American crude export facility located in Texas, which significantly advanced its export strategy to the coast Gulf of United States, the stock is performing well.

In addition, he also indicated that the construction of his three offshore wind projects in France is progressing according to schedule and is expected to combine for 1.4 gigawatts of green power generation capacity. And in keeping with green energy, the energy giant also recently announced a partnership with Vanguard Renewables to build eight renewable natural gas facilities along Enbridge’s massive gas transmission system in the United States. United.

So what?

Investors and analysts weren’t expecting a major recovery from Enbridge, in large part because the stock has such a resilient business model and wasn’t so badly affected by the pandemic in the first place. Nevertheless, these results are impressive and show that the company is progressing well and is looking to the future with its many growth plans.

It is also positive that Enbridge has reaffirmed its guidance for 2021. Enbridge expects to achieve EBITDA between $ 13.9 billion and $ 14.3 billion. Additionally, she expects to earn distributable cash flow per share between $ 4.70 and $ 5.00.

So overall it was another impressive quarter for blue chip stocks. And while these strong earnings are not surprising, they are a reminder of just how high quality Enbridge is for long-term investors.

Now what?

So far this year, Enbridge has already provided investors with a total return of over 35%. That’s a considerable amount for a company with a market capitalization north of $ 100 billion. However, after reporting a 23% increase in earnings and several high potential growth initiatives, Enbridge shares continue to look like one of the best investments you can buy in the long term.

The dividend aristocrat has now increased his payout every year for over a quarter of a century. In addition, the stock is returning an impressive 6.4% today.

So if you are looking for high quality stocks that you can be sure you own for the long haul, Enbridge is one of the best in Canada.


Source link

]]>